成人青光眼二次Ahmed阀植入的长期结局
该回顾性介入病例系列纳入1994至2016年间在同一眼序贯植入第二枚Ahmed青光眼阀的110眼(104例患者),平均随访5.0年。5年Kaplan-Meier生存率在三种成功标准下分别为57%、51%和30%。作者结论认为第二枚Ahmed阀对首枚阀后仍需进一步降眼压的患者有效,成功率与初次Ahmed阀植入及既往植入引流装置眼的 trabeculectomy 相当。
要点
- 5年生存率在标准1(眼压≤21 mmHg且降幅20%)、标准2(眼压≤18 mmHg且降幅25%)、标准3(眼压≤15 mmHg且降幅30%)下分别为57%、51%、30%。
- 作者结论认为第二枚Ahmed阀对首枚阀后眼压仍不达标者有效,成功率与初次Ahmed阀植入相当。
- 作者结论认为第二枚Ahmed阀成功率与既往植入青光眼引流装置眼的 trabeculectomy 相当。
核心结论
- 作者结论认为,第二枚Ahmed阀对首枚Ahmed阀后仍需进一步降眼压的患者有效。
- 作者结论认为,第二枚Ahmed阀的成功率与初次Ahmed阀植入相当,也与既往植入青光眼引流装置眼的 trabeculectomy 相当。
- 作者结论认为,第二枚Ahmed阀是首枚Ahmed阀后眼压不达标眼的可行选择。
研究设计与样本
- 回顾性介入病例系列,纳入1994至2016年间在同一眼序贯植入第二枚Ahmed阀的患者。
- 共纳入104例患者的110眼,平均随访5.0年(四分位距1.6-7.33年)。
- 第二次Ahmed阀植入时中位年龄68.0岁(四分位距53.5-77.9岁),两次手术间中位时间2.1年(四分位距0.7-4.0年)。
- 主要分析为各成功标准的5年Kaplan-Meier生存率。
主要发现
- 标准1(眼压≤21 mmHg且眼压降幅20%)的5年Kaplan-Meier生存率为57%。
- 标准2(眼压≤18 mmHg且眼压降幅25%)的5年Kaplan-Meier生存率为51%。
- 标准3(眼压≤15 mmHg且眼压降幅30%)的5年Kaplan-Meier生存率为30%。
关键数值与推荐
- 成功标准1:眼压≤21 mmHg且眼压降幅20%。
- 成功标准2:眼压≤18 mmHg且眼压降幅25%。
- 成功标准3:眼压≤15 mmHg且眼压降幅30%。
- 失败判定:术后至少3个月时连续两次随访未达到成功标准。
- 失败还包括:丧失光感、需额外青光眼手术、低眼压性黄斑病变及严重并发症。
临床怎么用
- 作者结论认为,第二枚Ahmed阀是首枚Ahmed阀后眼压不达标眼的可行选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the long-term outcomes of second Ahmed glaucoma valve (AGV) implants in eyes with glaucoma. DESIGN: Retrospective interventional case series. METHODS: Patients with sequential second Ahmed valves implanted in the same eye from 1994 to 2016 were included. Success was defined with 3 criteria: (1) intraocular pressure (IOP) ≤ 21 mm Hg and IOP reduction of 20%; (2) IOP ≤ 18 mm Hg and IOP reduction of 25%; and (3) IOP ≤15 mm Hg and IOP reduction of 30%. The primary analysis was the 5-year Kaplan-Meier survival rate for each criterion. Failure was established when the success criterion was not met at 2 consecutive visits at least 3 months after the surgery. Loss of light perception, requirement for additional glaucoma surgery, hypotony maculopathy, and serious complications were also considered failures. RESULTS: One hundred ten eyes from 104 patients were included with a mean follow-up of 5.0 years (interquartile range [IQR] 1.6-7.33 years). The median (IQR) age at the second AGV was 68.0 (53.5-77.9) years. The median (IQR) time between surgeries was 2.1 (0.7-4.0) years. The 5-year Kaplan-Meier survival rates were 57%, 51%, and 30% for criteria 1, 2, and 3, respectively. CONCLUSION: A second AGV is effective in reducing IOP in patients who require additional IOP lowering after a first AGV. The success rates are comparable to primary AGV implantation, and to trabeculectomy in eyes with a previously implanted glaucoma drainage device. A second AGV is a viable option in eyes with inadequate IOP levels after a primary AGV.
引用
- Fatehi N, Morales E, Parivisutt N, et al. Long-term Outcome of Second Ahmed Valves in Adult Glaucoma. Am J Ophthalmol. 2017. PMID: 29199011. doi:10.1016/j.ajo.2017.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。